Literature DB >> 8054271

Enhancement of in vitro prostaglandin E2 production by mouse fibrosarcoma cells after co-culture with various anti-tumour effector cells.

F Okada1, M Hosokawa, J Hasegawa, Y Kuramitsu, K Nakai, L Yuan, H Lao, H Kobayashi, N Takeichi.   

Abstract

We have previously reported that an increase in the production of immunosuppressive prostaglandin E2 by a QR tumour (QR-32) is accompanied by progressive growth of the tumour in syngeneic C57BL/6 mice. In order to determine what kinds of cell and factor(s) enable QR-32 cells to promote PGE2 production, we investigated the amounts of PGE2 in the supernatant of QR-32 cells by co-culturing them with various anti-tumour effector cells. Significantly high levels of PGE2 production were observed when the QR-32 cells were co-cultured with lymphokine-activated killer (LAK) cells, natural killer (NK) cells, polymorphonuclear (PMN) leucocytes and streptococcal preparation (OK432)-activated or resident peritoneal macrophages (activated and resident macrophages). On the other hand, PGE2 production was not increased when QR-32 cells were co-cultured with cytotoxic T lymphocytes (CTLs) specific to QR-32 cells. The high levels of PGE2 production were partially or totally inhibited by the presence of radical scavengers such as superoxide dismutase (SOD), catalase and mannitol, although the cytotoxicity of LAK cells was not. We also exposed QR-32 cells to human recombinant cytokines and the growth factors which are produced when anti-tumour effector cells come in contact with tumour cells. Significant PGE2 production by QR-32 cells was observed when the cells were treated with interferon alpha (IFN-alpha), tumour necrosis factor alpha (TNF-alpha) and transforming growth factor beta (TGF-beta) (all P < 0.001). These results suggest that oxygen radicals produced by anti-tumour effector cells and inflammatory cytokines provoke QR-32 cells to produce large amounts of immunosuppressive PGE2.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8054271      PMCID: PMC2033504          DOI: 10.1038/bjc.1994.285

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  An improved technique for the isolation of lymphocytes from small volumes of peripheral mouse blood.

Authors:  F Mizobe; E Martial; S Colby-Germinario; B G Livett
Journal:  J Immunol Methods       Date:  1982       Impact factor: 2.303

2.  Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice.

Authors:  N R Lynch; J C Salomon
Journal:  J Natl Cancer Inst       Date:  1979-01       Impact factor: 13.506

3.  Enhancement of immune function and tumor growth inhibition by antibodies against prostaglandin E2.

Authors:  M R Young; M Dizer
Journal:  Immunol Commun       Date:  1983

4.  Abnormalities of quantitative dinitrochlorobenzene sensitization in cancer patients: correlation with tumor stage and histology.

Authors:  W J Catalona; P B Chretien
Journal:  Cancer       Date:  1973-02       Impact factor: 6.860

Review 5.  Identification and activation of tumor-reactive cells for adoptive immunotherapy.

Authors:  P L Triozzi
Journal:  Stem Cells       Date:  1993-05       Impact factor: 6.277

6.  Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells.

Authors:  P H Rolland; P M Martin; J Jacquemier; A M Rolland; M Toga
Journal:  J Natl Cancer Inst       Date:  1980-05       Impact factor: 13.506

7.  Lymphokine regulation of activated (G1) lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin 2 production.

Authors:  C Walker; F Kristensen; F Bettens; A L deWeck
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

8.  Cytotoxic cells induced in tumor-bearing rats by a streptococcus preparation (OK-432).

Authors:  H Hojo; Y Hashimoto
Journal:  Gan       Date:  1981-10

9.  Immunosuppression in a murine B cell leukemia (BCL1): role of an adherent cell in the suppression of primary in vitro antibody responses.

Authors:  S A Anderson; P C Isakson; E Puré; M Muirhead; J W Uhr; E S Vitetta
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

10.  A rapid method for the isolation of metastasizing tumour cells from internal organs with the help of isopycnic density-gradient centrifugation in Percoll.

Authors:  K Bosslet; R Ruffmann; P Altevogt; V Schirrmacher
Journal:  Br J Cancer       Date:  1981-09       Impact factor: 7.640

View more
  7 in total

1.  Thymosin-beta4 regulates motility and metastasis of malignant mouse fibrosarcoma cells.

Authors:  Tokushige Kobayashi; Futoshi Okada; Nobuyuki Fujii; Naoko Tomita; Satoru Ito; Hiroshi Tazawa; Tetsuya Aoyama; Sung Ki Choi; Toshiyuki Shibata; Hisakazu Fujita; Masuo Hosokawa
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

2.  Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression.

Authors:  Hiroshi Tazawa; Futoshi Okada; Tokushige Kobayashi; Mitsuhiro Tada; Yukiko Mori; Yoshie Une; Fujiro Sendo; Masanobu Kobayashi; Masuo Hosokawa
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

3.  Nano-scaled particles of titanium dioxide convert benign mouse fibrosarcoma cells into aggressive tumor cells.

Authors:  Kunishige Onuma; Yu Sato; Satomi Ogawara; Nobuyuki Shirasawa; Masanobu Kobayashi; Jun Yoshitake; Tetsuhiko Yoshimura; Masaaki Iigo; Junichi Fujii; Futoshi Okada
Journal:  Am J Pathol       Date:  2009-10-08       Impact factor: 4.307

4.  Inflammatory cell-mediated tumour progression and minisatellite mutation correlate with the decrease of antioxidative enzymes in murine fibrosarcoma cells.

Authors:  F Okada; K Nakai; T Kobayashi; T Shibata; S Tagami; Y Kawakami; T Kitazawa; R Kominami; S Yoshimura; K Suzuki; N Taniguchi; O Inanami; M Kuwabara; H Kishida; D Nakae; Y Konishi; T Moriuchi; M Hosokawa
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

5.  Prevention of inflammation-mediated acquisition of metastatic properties of benign mouse fibrosarcoma cells by administration of an orally available superoxide dismutase.

Authors:  F Okada; H Shionoya; M Kobayashi; T Kobayashi; H Tazawa; K Onuma; Y Iuchi; N Matsubara; T Ijichi; B Dugas; M Hosokawa
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

6.  Inhibitory effect of a traditional Chinese medicine, Juzen-taiho-to, on progressive growth of weakly malignant clone cells derived from murine fibrosarcoma.

Authors:  Y Ohnishi; H Fujii; F Kimura; T Mishima; J Murata; K Tazawa; M Fujimaki; F Okada; M Hosokawa; I Saiki
Journal:  Jpn J Cancer Res       Date:  1996-10

7.  Cancer cell progression and chemoimmunotherapy--dual effects in the induction of resistance to therapy.

Authors:  J Hamuro; T Kikuchi; F Takatsuki; M Suzuki
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.